Abselion has announced the appointment of Dale Gordon as Chair of the Board of Directors.
His appointment strengthens governance and board-level expertise at Abselion, adding experienced commercial and bioprocess leadership as the company builds on the recent establishment of its US subsidiary and continues to develop its global engagement.
Abselion is committed to building a well-governed organisation that can support collaboration and reliable delivery as interest in its Amperia protein quantification system grows internationally.
As Chair, Dale will help to ensure sustainable growth and long-term value creation to meet the needs of academic, biotech and pharma teams working across biologics characterisation, development and manufacturing workflows.
Dale brings more than 30 years’ experience across the life sciences sector, with a background spanning bioprocessing, company building and board leadership.
Most recently, he served as CEO of Mirus Bio, a leading provider of transfection technologies widely used in viral vector production, where he led the business through a period of significant growth and strategic development.
He was also CEO at Gemini Bio and held leadership roles at GE Life Sciences (now Cytiva) and Merck Millipore.
